Streetbeat News

Regulatory

ALRN

Aileron Therapeutics received a letter from Nasdaq on Feb 29, confirming that the company has regained compliance for continued listing on Nasdaq, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 9:16 pm

AADI

Aadi Bioscience, Inc. (NASDAQ:AADI) announced long-term efficacy and safety results from its Phase 2 AMPECT study of nab-sirolimus for treating malignant PEComa, showing significant survival benefits. The study, published in the Journal of Clinical Oncology, reported a median duration of response of 39.7 months and median survival over 53 months, surpassing historical median survival rates of 16 to 29 months. The confirmed overall response rate was 38.7%, with durable responses and tolerable safety profile.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 9:14 pm

CTKB

Cytek Biosciences Inc has filed for a non-timely 10-K with the U.S. SEC, indicating it will report un-remediated material weaknesses for the quarter ended Sept 30, 2023.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 9:14 pm

TPET

Trio Petroleum Corp (NYSE:TPET), a California-based oil and gas company, announced receiving a deficiency letter from NYSE American for not complying with listing standards due to low share prices. The company must demonstrate price improvement by August 26, 2024, and is considering operations in the McCool field and a potential reverse stock split as measures to regain compliance.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 9:10 pm

MEGL

Magic Empire Global Limited (MEGL) received a Nasdaq notification on February 28, 2024, for failing to meet the minimum bid price requirement of $1 per share from January 16, 2024, to February 27, 2024, under Nasdaq Listing Rules 5550(a)(2).

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 9:09 pm

TPCS

TechPrecision Corporation (NASDAQ:TPCS) received a notice from Nasdaq on February 26, 2024, for not complying with the Nasdaq Listing Rule 5250(c)(1) due to the late filing of its Q3 Form 10-Q. The company was given 60 days to submit a compliance plan but expects to cure the deficiency by filing the Q3 Form 10-Q today.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 9:07 pm

CURO

CURO Group Holdings Corp. (NYSE:CURO) has entered into forbearance agreements with the majority of its lenders and obtained a waiver for certain defaults, allowing the company to continue discussions to strengthen its balance sheet. The agreements prevent lenders from exercising remedies against CURO until March 18, 2024, aiming to improve financial flexibility and support growth. Details are disclosed in a Form 8-K filed with the SEC.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 9:06 pm

CVS

WBA

CVS Health Corp (CVS) and Walgreens Boots Alliance Inc (WBA) announced plans to dispense the abortion pill mifepristone in select states, following FDA guidelines. The rollout will begin in states like New York, Pennsylvania, Massachusetts, California, and Illinois for Walgreens, and Massachusetts and Rhode Island for CVS. The expansion will continue in states where abortion is legal and pharmacy dispensation is allowed. The Supreme Court's upcoming decision on mifepristone could impact its availability. CVS stock is down 0.55%, while WBA shares are up 0.98%.

Portfolio Pulse from Vandana Singh

March 01, 2024 | 8:41 pm

GBTC

Grayscale Investments is seeking SEC approval for options trading on its Bitcoin ETF, GBTC, to diversify its investor base and enhance shareholder value. CEO Michael Sonnenshein emphasizes the importance of this move, especially given Bitcoin's recent 47% monthly increase. The approval process may be complex, involving both the SEC and CFTC, due to Bitcoin's commodity classification. Options trading could bring significant capital into Bitcoin ETFs, improve price discovery, and integrate Bitcoin more closely into the regulated financial ecosystem.

Portfolio Pulse from Murtuza Merchant

March 01, 2024 | 8:22 pm

GEHC

The FDA has classified the recall of Datex-Ohmeda's EVair air compressors as a Class I recall due to the discovery of formaldehyde emissions under specific conditions. These compressors are used with Engstrom Carestation or Pro ventilators.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 8:07 pm